(E)-(S)-2-Isopropyl-7-methyl-oct-4-enoic acid ((1R,2S)-2-hydroxy-1-methyl-2-phenyl-ethyl)-methyl-amide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (E)-(S)-2-Isopropyl-7-methyl-oct-4-enoic acid ((1R,2S)-2-hydroxy-1-methyl-2-phenyl-ethyl)-methyl-amide
• 英文别名: (E,2S)-N-[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]-N,7-dimethyl-2-propan-2-yloct-4-enamide
• 化学式: C₂₂H₃₅NO₂
• 分子量: 345.525
• InChiKey: BIOUPKGCBQKLPV-MNMSUMMTSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.9
• 重原子数：
  25
• 可旋转键数：
  9
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.59
• 拓扑面积：
  40.5
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (E)-(S)-2-Isopropyl-7-methyl-oct-4-enoic acid ((1R,2S)-2-hydroxy-1-methyl-2-phenyl-ethyl)-methyl-amide 在 palladium on activated charcoal N-溴代丁二酰亚胺(NBS) 、 氢气 、 溶剂黄146 、 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 乙醇 、 水 为溶剂， 生成 (2R,4S,5S)-2-(2-propyl)-4-hydroxy-5-<(tert-butyloxycarbonyl)amino>-7-methyloctanoic acid δ-lactone
  参考文献：
  名称：

  Design of Substrate-Based Inhibitors of Human β-Secretase

  摘要：

  By use of the effectively cleaved beta-secretase (BACE) substrate (1), incorporation of a statine in P-l resulted in a weak inhibitor 13 of the enzyme. Further substitution of P-1'-Asp by P-1'-Val in 13 results in a potent inhibitor 22 of BACE. Removal of the P-10-P-5 residues on the N-terminal part of inhibitor 22 resulted in no loss of potency (23). C-terminal truncations of inhibitor 22 generally led to significant loss of potency.

  DOI：

  10.1021/jm0155695

文献信息

• Design of Substrate-Based Inhibitors of Human β-Secretase
  作者：Jay S. Tung、David L. Davis、John P. Anderson、Don E. Walker、Shumeye Mamo、Nancy Jewett、Roy K. Hom、Sukanto Sinha、Eugene D. Thorsett、Varghese John

  DOI：10.1021/jm0155695

  日期：2002.1.1

  By use of the effectively cleaved beta-secretase (BACE) substrate (1), incorporation of a statine in P-l resulted in a weak inhibitor 13 of the enzyme. Further substitution of P-1'-Asp by P-1'-Val in 13 results in a potent inhibitor 22 of BACE. Removal of the P-10-P-5 residues on the N-terminal part of inhibitor 22 resulted in no loss of potency (23). C-terminal truncations of inhibitor 22 generally led to significant loss of potency.